Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma
Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed